1. Development and Characterization of Mouse Monoclonal Antibodies Specific for Clostridiodes (Clostridium) difficile Lipoteichoic Acid
- Author
-
Nicolas Gisch, Martin A Rossotti, Wouter F. J. Hogendorf, Susan M. Logan, Henk van Faassen, Chantelle M. Cairns, Kevin A. Henry, Annie Aubry, Greg Hussack, Andrew D. Cox, Frank St. Michael, and Christian Pedersen
- Subjects
0301 basic medicine ,biology ,010405 organic chemistry ,Chemistry ,medicine.drug_class ,General Medicine ,Pseudomembranous colitis ,Clostridium difficile ,Monoclonal antibody ,01 natural sciences ,Biochemistry ,Epitope ,0104 chemical sciences ,Microbiology ,03 medical and health sciences ,030104 developmental biology ,Antigen ,biology.protein ,medicine ,Molecular Medicine ,Lipoteichoic acid ,Antibody ,Antitoxin - Abstract
Clostridiodes (Clostridium) difficile is an anaerobic Gram-positive, spore-forming nosocomial, gastrointestinal pathogen causing C. difficile-associated disease with symptoms ranging from mild cases of antibiotic-associated diarrhea to fatal pseudomembranous colitis. We developed murine monoclonal antibodies (mAbs) specific for a conserved cell surface antigen, lipoteichoic acid (LTA)of C. difficile. The mAbs were characterized in terms of their thermal stability, solubility, and their binding to LTA by surface plasmon resonance and competitive ELISA. Synthetic LTA molecules were prepared in order to better define the minimum epitope required to mimic the natural antigen, and three repeat units of the polymer were required for optimal recognition. One of the murine mAbs was chimerized with human constant region domains and was found to recognize the target antigen identically to the mouse version. These mAbs may be useful as therapeutics (standalone, in conjunction with known antitoxin approaches, or as delivery vehicles for antibody drug conjugates targeting the bacterium), as diagnostic agents, and in infection control applications.
- Published
- 2020
- Full Text
- View/download PDF